P63.10 Safety of Simultaneously Performed Radiotherapy in Patients With Small-Cell Lung Cancer Undergoing Atezolizumab Treatment

In September 2019 Atezolizumab was approved for extended disease small cell lung cancer (ED-SCLC) in combination with cytotoxic chemotherapy by the European Medicines Agency (EMA). In the clinical trial IMpower133 only 22 out of 201 patients received prophylactic cranial radiotherapy (PCI) during their treatment with Atezolizumab (either during induction chemo-/immunotherapy or during maintenance immunotherapy). To our knowledge, no other clinical studies have reported efficacy or safety regarding the combination of radiotherapy (PCI, whole brain radiotherapy (WBRT) or consolidating thoracic radiotherapy) with Atezolizumab as single agent or in combination with chemotherapy.